ストックスクリーナーアプリを入手
58.61
0.24%
-0.14
アフターアワーズ：
58.60
-0.010
-0.02%
前日終値:
$58.75
開ける：
$58.95
24時間の取引高:
2.60M
Relative Volume:
0.84
時価総額：
$26.10B
収益：
$2.44B
当期純損益:
$1.36B
株価収益率:
30.70
EPS:
1.9093
ネットキャッシュフロー:
$574.14M
1週間 パフォーマンス:
-8.36%
1か月 パフォーマンス:
+1.42%
6か月 パフォーマンス:
+25.53%
1年 パフォーマンス:
+59.70%
1日の値動き範囲:
$58.35
$59.54
1週間の範囲:
$58.35
$60.86
52週間の値動き範囲:
$34.63
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.61 | 26.10B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
California State Teachers Retirement System Increases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - moomoo.com
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - streetinsider.com
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma (RPRX) Stock Forecast and Price Target 2026 - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma Updates on Novartis' HORIZON Trial Results - intellectia.ai
Royalty Pharma expects modest return despite pelacarsen trial failure By Investing.com - Investing.com Nigeria
Royalty Pharma expects modest return despite pelacarsen trial failure - Investing.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - The Manila Times
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Royalty Pharma Slides as Higher-Rate Jitters Seem to Outweigh Recent Strong Results - Quiver Quantitative
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - marketbeat.com
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Strong Buy Ratings and Promising Growth in the Biotech Sector - DirectorsTalk Interviews
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal? - Sahm
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy" - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
0.29%
大文字化:
|
ボリューム (24 時間):